hotspot -WSS

hotspot

author：focus 2025-09-28 18:20:30 - browse：5

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The Readout: Amylyx, Alumis, and Lundbeck drug updates

entertainment

WSS

Medicare says breakthrough device reimbursement rule to come by summer

Readout LOUD podcast: brain research, obesity drug sales, Novartis

How to bring more disabled researchers into academia

Novo Nordisk obesity pill bests Wegovy in early trial

Making AI in medicine accessible to smaller, and rural hospitals

After gene therapy, two congenitally deaf children hear for the first time

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

H5N1 bird flu: what we're starting to learn about infection in cows

In Memoriam: Notable people who died in 2023

Air quality improving but still lags in Black, Hispanic communities

Hollywood unions extend contract negotiations for actors

Change Healthcare payments predicted restored March 15

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: What to know about H5N1 bird flu

Bright Health sells Medicare Advantage business to Molina

Amylyx ALS drug fails large clinical trial

leisure time

NEJM study link tiny plastics in blood vessels to heart problems

Telehealth startups turn to complex chronic diseases

Amylyx ALS drug failure raises questions and concerns

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

The problem with charging patients to message their doctors

Wikipedia

hotspot

entertainment

hotspot